For long HCCs have been classified based on transcriptomic profile, and works from different teams yields to different classifications108–113, ultimately integrated into a system where HCC are divided into two groups: proliferative, associated with poor outcome and TP53 mutation and non-proliferative, associated with better outcome and β-catenin (CTNNB1) mutation. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.